Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
OneSource Specialty Pharma
Mid Cap•1,412 Employees•IPO 2025
Current Price
₹1473.90
-41 (-2.71%)Updated
Today's Range
₹1445.80
₹1536.60
₹1473.90
52 Week Range
52W Low₹1057.00
52W High₹2248.00
₹1473.90
Downside39.44%
Upside52.52%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹14,769.52 Cr
Market Cap
Total market value of companyP/E Ratio
679.96
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
3.57
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹1.76
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
-%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
5.52%
ROCE
Return on Capital Employed. >15% is goodNet Margin
1.42%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
-%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
12.00%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
268.00%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.16
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹513.87
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
29.80%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •The company reported a 12.00% quarter-on-quarter sales growth, indicating a positive trend in revenue generation. This is competitive with peers like Divi's Lab (13.79%) and Mankind Pharma (24.50%).
- •With a debt-to-equity ratio of 0.13, OneSource maintains a very healthy balance sheet, suggesting low financial risk and strong solvency compared to industry averages.
Weaknesses
5 points- •OneSource's P/E ratio of 240.00 is significantly higher than its peers (e.g., Sun Pharma 35.90, Cipla 23.66), suggesting the stock is overvalued relative to its current earnings.
- •Despite a 268.00% quarterly profit variance, the latest net profit for 2025-06 was negative at -0.19 Cr, highlighting inconsistent and often unprofitable operations.
Opportunities
3 points- •As a player in the Pharmaceuticals industry, OneSource can capitalize on the overall sector expansion driven by increasing healthcare demand, R&D advancements, and global market access.
- •The significant positive net profit of 98.50 Cr in 2025-03 suggests the company has the potential to achieve consistent profitability, if recent losses can be addressed.
Threats
3 points- •OneSource faces stiff competition from larger, more profitable, and established players in the Pharmaceuticals sector like Sun Pharma and Cipla, which have significantly higher ROCE and lower P/E ratios.
- •The pharmaceutical sector is highly regulated, and changes in drug pricing policies, approval processes, or manufacturing standards could negatively impact OneSource's operations and profitability.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
Sajitha Pillai | 05 Feb 2025 | 06 Feb 2025 | 40,000 | 7,500 | ₹1,532.06 | SELL |
Hemalatha Pillai | 03 Feb 2025 | 06 Feb 2025 | 3,380 | 18,000 | ₹1,453.07 | SELL |
Neeraj Sharma | 03 Feb 2025 | 06 Feb 2025 | 1.36 L | 20,000 | ₹1,487.15 | SELL |
Vineetha Mohankumar Pillai | 31 Jan 2025 | 06 Feb 2025 | 47,500 | 47,500 | ₹1,565.38 | SELL |
Padmakumar Karunakaran Pillai | 31 Jan 2025 | 06 Feb 2025 | 43,242 | 50,000 | ₹1,558.73 | SELL |
Hemalatha Pillai | 31 Jan 2025 | 06 Feb 2025 | 21,380 | 12,000 | ₹1,579.62 | SELL |
Tenshi Pharmaceuticals Private Limited | 31 Jan 2025 | 06 Feb 2025 | 2.05 Cr | 33.01 L | ₹1,531.74 | SELL |
Pronomz Ventures LLP | 31 Jan 2025 | 06 Feb 2025 | 77.85 L | 5.83 L | ₹1,545 | SELL |
Sajitha Pillai | 06 Feb 2025 | 10 Feb 2025 | 35,000 | 5,000 | ₹1,547.84 | SELL |
Pronomz Ventures LLP | 13 Jun 2025 | 16 Jun 2025 | 26.82 L | 51.03 L | ₹1,977 | SELL |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1706.67 | +₹232.77 | +15.79% |
| R3 | ₹1615.87 | +₹141.97 | +9.63% |
| R2 | ₹1576.23 | +₹102.33 | +6.94% |
| R1 | ₹1525.07 | +₹51.17 | +3.47% |
| PIVOT | ₹1485.43 | 11.53 | 0.78% |
| CURRENT | ₹1473.90 | - | - |
| S1 | ₹1252.67 | -₹221.23 | -15.01% |
| S2 | ₹1343.47 | -₹130.43 | -8.85% |
| S3 | ₹1394.63 | -₹79.27 | -5.38% |
| S4 | ₹1434.27 | -₹39.63 | -2.69% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-4.6% vs avg
2.87L
(10 Mar 2026)Delivery %-10.2% vs avg
38.6%
(10 Mar 2026)Avg Volume (20D)20-day average
3.01L
(10 Feb - 10 Mar)Avg Delivery %Trend ↓
48.8%
(10 Feb - 10 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Divis Laboratories Ltd
1.64L ₹ Cr
Best Profit Growth
Sai Life Sciences Ltd
548.00 %
Highest Dividend Yield
Windlas Biotech Ltd
1.29 %
Peer Comparison
| Company Name |
|---|
 Akums Drugs & Pharmaceuticals Ltd |
 Anthem Biosciences Ltd |
 Dishman Carbogen Amcis Ltd |
 Divis Laboratories Ltd |
 Indegene Ltd |
 Innova Captab Ltd |
 Sai Life Sciences Ltd |
 Suven Life Sciences Ltd |
 Syngene International Ltd |
 Vimta Labs Ltd |
 Windlas Biotech Ltd |
About
OneSource Specialty Pharma Ltd
ONESOURCE Specialty Pharma Limited is a biopharmaceutical company headquartered in Bengaluru, India, focusing on the research, development, manufacturing, and commercialization of biological drug products. Their primary market is both within India and internationally. The company's core business revolves around providing high-quality biologics in various injectable formats, catering to a broad spectrum of pharmaceutical needs.
A significant aspect of ONESOURCE's operations is its comprehensive contract development and manufacturing organization (CDMO) services. These services span the entire lifecycle of drug development, from the preclinical and clinical phases all the way through to the commercial supply of biologics. This end-to-end approach offers clients a streamlined and integrated solution for bringing their biopharmaceutical products to market.
Beyond its CDMO capabilities, ONESOURCE also boasts a robust manufacturing portfolio. This includes the production of a diverse range of drug delivery devices, such as prefilled syringes, various types of pen injectors, and autoinjectors. In addition to these drug-device combinations, they manufacture sterile injectables, soft gelatin capsules, and a variety of biologics solutions. Their manufacturing expertise extends to diverse biopharmaceutical modalities such as microbial and mammalian cell line biopharmaceuticals, cell and gene therapy products, and RNA-based therapeutics.
ONESOURCE's wide-ranging capabilities and integrated approach position it as a significant player in the global biopharmaceutical landscape. The company's commitment to quality and its broad service offering enable it to support the development and supply of a wide variety of biologics, contributing to advancements in healthcare both domestically and internationally. Its recent name change from Stelis Biopharma Limited to ONESOURCE Specialty Pharma Limited reflects a strategic shift towards highlighting its comprehensive and integrated service offering to clients.
COMPANY FACTS - ONESOURCE
Registered Address
Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road
Bangalore
KARNATAKA
IN
Tel: 918067840738
Website:https://www.onesourcecdmo.com/
Investor Relations:http://www.onesourcecdmo.com/investor-relations/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Life Sciences Tools & Services
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,412
IPO Date: 24/01/2025
MANAGEMENT - ONESOURCE
Mr. Anurag Bhagania
Chief Financial Officer
Ms. Allada Trisha
Compliance Officer, Company Secretary
Neeraj Sharma
Managing Director
Pudhucode Kannan
Whole-Time Director
Mr. Bernhard Bernhard
Chief Quality Officer
Mr. Bhushan Bopardikar
Director
Arun Pillai
Director (Promoter)
Mr. Bharat Shah
Director
Mr. Deepak Vaidya
Independent Director
Dr. Claudio Albrecht
Additional Non-Executive Independent Director
Mr. Vijay Karwal
Additional Non-Executive Independent Director
Ms. Debarati Sen
Additional Non-Executive Independent Director
Investor Questions Answered
OneSource Specialty Pharma Ltd (ONESOURCE) Stock FAQs
Get answers to the most common questions about OneSource Specialty Pharma Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of OneSource Specialty Pharma Ltd (ONESOURCE) is ₹1,473.9. Today, the stock has declined by ₹41.00 (2.71%), trading in a range of ₹1,445.8 to ₹1,536.6. The stock opened at ₹1,498 with a trading volume of 2,87,281 shares.
OneSource Specialty Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹14,769.52 crores, P/E ratio of 679.96, ROE of 0.00%, and ROCE of 5.52%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of OneSource Specialty Pharma Ltd (ONESOURCE) is ₹2,248, while the 52-week low is ₹1,057. Currently trading at ₹1,473.9, the stock is 35.0% away from its 52-week low and 34.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy OneSource Specialty Pharma Ltd stock at ₹1,473.9 depends on multiple factors. The stock is currently trading with a P/E ratio of 679.96 and P/B ratio of N/A. Today's performance shows a loss of 2.71%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
OneSource Specialty Pharma Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹1,473.9, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
OneSource Specialty Pharma Ltd's key financial metrics include: P/E Ratio: 679.96, P/B Ratio: N/A, ROE: 0.00%, ROCE: 5.52%, Dividend Yield: 0.00%, EPS: ₹1.76, Book Value: ₹513.87, Debt-to-Equity: 0.16, and Current Ratio: N/A. The company's market cap stands at ₹14,769.52 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
OneSource Specialty Pharma Ltd stock opened at ₹1,498 and is currently trading at ₹1,473.9, showing a decline of ₹41.00 (2.71%). The intraday high is ₹1,536.6 and low is ₹1,445.8. The trading volume stands at 2,87,281 shares, indicating moderate market participation today.
OneSource Specialty Pharma Ltd has a Price-to-Earnings (P/E) ratio of 679.96, which means investors are willing to pay ₹679.96 for every ₹1 of earnings. With an EPS of ₹1.76, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
OneSource Specialty Pharma Ltd has a market capitalization of ₹14,769.52 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹1,473.9) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
OneSource Specialty Pharma Ltd has a book value of ₹513.87 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,473.9, which is 186.8% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
OneSource Specialty Pharma Ltd has a Return on Equity (ROE) of 0.00% and Return on Capital Employed (ROCE) of 5.52%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
OneSource Specialty Pharma Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
OneSource Specialty Pharma Ltd has a debt-to-equity ratio of 0.16, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
OneSource Specialty Pharma Ltd has an Earnings Per Share (EPS) of ₹1.76, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,473.9 and P/E ratio of 679.96, investors are paying 679.96 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
OneSource Specialty Pharma Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
OneSource Specialty Pharma Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze OneSource Specialty Pharma Ltd stock, consider: 1) Fundamental Analysis - Review P/E (679.96), ROE (0.00%), debt-to-equity (0.16), and growth rates. 2) Technical Analysis - Check 52-week range (₹1057.00 - ₹2248.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1473.90) with book value (₹513.87) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of OneSource Specialty Pharma Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,473.9 is 147290x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in OneSource Specialty Pharma Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1057.00 - ₹2248.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.16 indicates leverage. 4) Liquidity Risk - Based on trading volume of 2,87,281 shares. 5) Valuation Risk - P/E of 679.96 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
OneSource Specialty Pharma Ltd operates in the industry with key metrics: P/E ratio of 679.96, ROE of 0.00%, market cap of ₹14,769.52 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.16), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for OneSource Specialty Pharma Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,473.9, with a 52-week range of ₹1057.00 to ₹2248.00. Based on fundamentals like P/E (679.96), ROE (0.00%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling OneSource Specialty Pharma Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1473.90. 2) Fundamental Deterioration - Declining ROE (currently 0.00%), increasing debt (D/E: 0.16), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for OneSource Specialty Pharma Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu